thiotepa has been researched along with Dysmyelopoietic Syndromes in 11 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 9.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 5.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| " This study reports the results of UD-CBT in 22 adults with hematologic malignancies following conditioning with thiotepa, busulfan, cyclophosphamide, and antithymocyte globulin in 21, with thiotepa, fludarabine, and antithymocyte globulin in 1, and graft-versus-host disease (GVHD) prophylaxis with cyclosporine and prednisone." | 5.09 | Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. ( Andreu, R; Barragán, E; Benlloch, L; Bolufer, P; Cervera, J; de La Rubia, J; García, I; Jarque, I; Jiménez, C; Larrea, L; Martín, G; Martínez, J; Marty, ML; Mollá, S; Moscardó, F; Planelles, D; Plumé, G; Regadera, AI; Saavedra, S; Sanz, GF; Sanz, MA; Senent, L; Soler, MA; Solves, P, 2001) |
| "Toxicity included mostly infections." | 2.75 | Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. ( Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cassanello, G | 1 |
| Serpenti, F | 1 |
| Bagnoli, F | 1 |
| Saporiti, G | 1 |
| Goldaniga, M | 1 |
| Cavallaro, F | 1 |
| Barbullushi, K | 1 |
| Bellani, V | 1 |
| Galassi, G | 1 |
| Onida, F | 1 |
| Ciurea, SO | 1 |
| Saliba, R | 1 |
| Rondon, G | 1 |
| Pesoa, S | 1 |
| Cano, P | 1 |
| Fernandez-Vina, M | 1 |
| Qureshi, S | 1 |
| Worth, LL | 1 |
| McMannis, J | 1 |
| Kebriaei, P | 1 |
| Jones, RB | 1 |
| Korbling, M | 1 |
| Qazilbash, M | 1 |
| Shpall, EJ | 1 |
| Giralt, S | 3 |
| de Lima, M | 1 |
| Champlin, RE | 1 |
| Gajewski, J | 2 |
| Fujimaki, K | 1 |
| Taguchi, J | 1 |
| Fujita, H | 1 |
| Hattori, M | 1 |
| Yamazaki, E | 1 |
| Takahashi, N | 1 |
| Fujisawa, S | 1 |
| Kanamori, H | 1 |
| Maruta, A | 1 |
| Ishigatsubo, Y | 1 |
| Przepiorka, D | 3 |
| Ippoliti, C | 1 |
| van Beisen, K | 1 |
| Mehra, R | 2 |
| Deisseroth, AB | 1 |
| Andersson, B | 1 |
| Luna, M | 1 |
| Cork, A | 1 |
| Lee, M | 1 |
| Bacigalupo, A | 2 |
| Van Lint, MT | 2 |
| Valbonesi, M | 1 |
| Lercari, G | 1 |
| Carlier, P | 1 |
| Lamparelli, T | 2 |
| Gualandi, F | 2 |
| Occhini, D | 1 |
| Bregante, S | 2 |
| Valeriani, A | 1 |
| Piaggio, G | 1 |
| Pitto, A | 2 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| De Stefano, G | 1 |
| Caimo, A | 1 |
| Sessarego, M | 2 |
| Worth, L | 1 |
| Tran, H | 1 |
| Petropoulos, D | 1 |
| Culbert, S | 1 |
| Mullen, C | 1 |
| Roberts, W | 1 |
| Chan, K | 1 |
| Raiola, AM | 1 |
| Mordini, N | 1 |
| Berisso, G | 1 |
| Frassoni, F | 1 |
| Fugazza, G | 1 |
| Di Stefano, F | 1 |
| Bieri, S | 1 |
| Helg, C | 1 |
| Chapuis, B | 1 |
| Miralbell, R | 1 |
| Bibawi, S | 1 |
| Abi-Said, D | 1 |
| Fayad, L | 1 |
| Anderlini, P | 1 |
| Ueno, NT | 1 |
| Khouri, I | 1 |
| Donato, M | 1 |
| Claxton, D | 1 |
| Braunschweig, I | 1 |
| van Besien, K | 1 |
| Andreeff, M | 1 |
| Andersson, BS | 1 |
| Estey, EH | 1 |
| Champlin, R | 1 |
| Sanz, GF | 1 |
| Saavedra, S | 1 |
| Planelles, D | 1 |
| Senent, L | 1 |
| Cervera, J | 1 |
| Barragán, E | 1 |
| Jiménez, C | 1 |
| Larrea, L | 1 |
| Martín, G | 1 |
| Martínez, J | 1 |
| Jarque, I | 1 |
| Moscardó, F | 1 |
| Plumé, G | 1 |
| Andreu, R | 1 |
| Regadera, AI | 1 |
| García, I | 1 |
| Mollá, S | 1 |
| Solves, P | 1 |
| de La Rubia, J | 1 |
| Bolufer, P | 1 |
| Benlloch, L | 1 |
| Soler, MA | 1 |
| Marty, ML | 1 |
| Sanz, MA | 1 |
| Silberberg, JM | 1 |
| Zarrabi, MH | 1 |
6 trials available for thiotepa and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2010 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone M | 1996 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 1999 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bon | 2001 |
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2001 |
5 other studies available for thiotepa and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2004 |
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Topics: Adult; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Administration Schedule; Female; Fo | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2001 |
Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature.
Topics: Administration, Intravesical; Aged; Carcinoma, Papillary; Carcinoma, Transitional Cell; Humans; Leuk | 1987 |